LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 6137 | 5418 | 1.1335 | 1.2457 |
| Hs 578T | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 765 | 3829 | 3101 | 1.2349 | 1.2203 |
| Hs 578T | SB590885 | 3.33 | uM | LJP5 | 72 | hr | 765 | 3864 | 3148 | 1.2276 | 1.2113 |
| Hs 578T | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 765 | 3770 | 3101 | 1.2154 | 1.2028 |
| Hs 578T | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 765 | 3768 | 3101 | 1.2151 | 1.2026 |
| BT-20 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 1334 | 4675 | 4033 | 1.1588 | 1.1931 |
| Hs 578T | SB590885 | 0.04 | uM | LJP5 | 72 | hr | 765 | 3790 | 3148 | 1.2041 | 1.1904 |
| Hs 578T | SB590885 | 1.11 | uM | LJP5 | 72 | hr | 765 | 3789 | 3148 | 1.2038 | 1.1903 |
| SK-BR-3 | HG-6-64-01 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5967 | 5418 | 1.1017 | 1.1866 |
| MCF7 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 6450 | 5445 | 1.1889 | 1.1853 |
| Hs 578T | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 765 | 3751 | 3148 | 1.1915 | 1.1790 |
| Hs 578T | SB590885 | 0.37 | uM | LJP5 | 72 | hr | 765 | 3748 | 3148 | 1.1907 | 1.1785 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6352 | 5752 | 1.1044 | 1.1760 |
| Hs 578T | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 765 | 3735 | 3148 | 1.1865 | 1.1747 |
| Hs 578T | SB590885 | 0.12 | uM | LJP5 | 72 | hr | 765 | 3734 | 3148 | 1.1863 | 1.1744 |
| BT-20 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1334 | 4437 | 3925 | 1.1302 | 1.1624 |
| BT-20 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1334 | 4411 | 3925 | 1.1235 | 1.1545 |
| SK-BR-3 | SB590885 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6271 | 5752 | 1.0903 | 1.1524 |
| Hs 578T | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 765 | 3596 | 3101 | 1.1593 | 1.1519 |
| Hs 578T | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 765 | 3587 | 3101 | 1.1563 | 1.1491 |
| SK-BR-3 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6256 | 5752 | 1.0876 | 1.1478 |
| SK-BR-3 | SB590885 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6254 | 5752 | 1.0872 | 1.1472 |
| SK-BR-3 | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6253 | 5752 | 1.0871 | 1.1469 |
| MCF7 | Imatinib | 0.12 | uM | LJP6 | 72 | hr | 1389 | 6237 | 5445 | 1.1474 | 1.1453 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6242 | 5752 | 1.0853 | 1.1439 |